A Malvern biotechnology company, Aclaris Therapeutics, said Friday that its drug to treat a common skin condition called seborrheic keratoses was approved by the U.S. Food and Drug Administration.

The treatment, called Eskata, is the first topical medicine for a type of noncancerous skin growth that affects more than 83 million American adults, and represents Aclaris’ first product.

The hydrogen peroxide solution, which is administered in a pen-type applicator in a physician’s office, dissolves the growths.

Read the full article at www.philly.com